Oncology PracticeCheckpoint inhibitors ‘viable treatment option’ in HIV-infected individualsFebruary 8, 2019Immuno-oncologyLung CancerSarcoma & GISTMelanoma
The Sarcoma JournalSorafenib extends PFS for refractory desmoid tumorsDecember 19, 2018Rare SarcomasSarcoma & GIST
The Sarcoma JournalReports from the annual meeting of The Connective Tissue Oncology Society held in Rome, November 14-17, 2018 Sarcoma of the Year: Intimal SarcomaDecember 17, 2018Rare SarcomasSarcoma & GIST
The Journal of Community and Supportive OncologyPatterns of malignancies in patients with HIV-AIDS: a single institution observational studyNovember 27, 2018Patient & Survivor CareSarcoma & GISTGynecologic CancerLymphoma & Plasma Cell Disorders
Oncology PracticeFDA approves larotrectinib for cancers with NTRK gene fusionsNovember 27, 2018Sarcoma & GISTRare DiseasesFibrosarcoma
The Journal of Community and Supportive OncologyImmunotherapy may hold the key to defeating virally associated cancersNovember 25, 2018Head & Neck/Thyroid CancersGenitourinary CancerGynecologic CancerGastroenterologyImmunotherapyLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell Disorders
The Journal of Community and Supportive OncologyPrimary renal synovial sarcoma – a diagnostic dilemmaOctober 28, 2018Sarcoma & GISTRare Sarcomas
Oncology PracticeTKIs and immunotherapy hold promise for alveolar soft part sarcomaOctober 23, 2018Sarcoma & GISTRare SarcomasImmuno-oncology
The Sarcoma JournalPredicting treatment response in leiomyosarcoma, liposarcomaOctober 5, 2018LeiomyosarcomaLiposarcomaSarcoma & GIST
Hematology NewsFDA lifts partial hold on tazemetostat trialsSeptember 30, 2018T Cell LymphomasLymphoma & Plasma Cell DisordersAggressive LymphomasFollicular LymphomaB Cell LymphomaSarcoma & GIST
Oncology PracticePARP inhibitor plus trabectedin shows promise for sarcomaSeptember 18, 2018Sarcoma & GIST
